132 related articles for article (PubMed ID: 33565809)
21. Protocol for Desensitization to Atezolizumab and Bevacizumab After Severe Anaphylaxis in the Treatment of Lung Adenocarcinoma.
Gonzalez-Diaz SN; Villarreal-Gonzalez RV; De Lira-Quezada CE; Rocha-Silva GK; Oyervides-Juarez VM; Vidal-Gutierrez O
J Investig Allergol Clin Immunol; 2021 Jun; 31(3):265-267. PubMed ID: 32856592
[No Abstract] [Full Text] [Related]
22. [Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment].
Cohen R; Pudlarz T; Garcia-Larnicol ML; Vernerey D; Dray X; Clavel L; Jary M; Piessen G; Zaanan A; Aparicio T; Louvet C; Tournigand C; Chibaudel B; Tougeron D; Guimbaud R; Benouna J; Adenis A; Sokol H; Borg C; Duval A; Svrcek M; André T
Bull Cancer; 2020 Apr; 107(4):438-446. PubMed ID: 32057467
[TBL] [Abstract][Full Text] [Related]
23. Metastatic cutaneous apocrine adenocarcinoma responsive to the programmed cell death protein 1 inhibitor pembrolizumab.
Rogatsch M; Schmid J; Lax S; Uranitsch M; Schmid-Zalaudek K; Giuffrida R; Zalaudek I
Eur J Cancer; 2018 Feb; 90():146-148. PubMed ID: 29237537
[No Abstract] [Full Text] [Related]
24. Perioperative chemotherapy is associated with a survival advantage in early stage adenocarcinoma of the pancreatic head.
Lutfi W; Talamonti MS; Kantor O; Wang CH; Liederbach E; Stocker SJ; Bentrem DJ; Roggin KK; Winchester DJ; Marsh R; Prinz RA; Baker MS
Surgery; 2016 Sep; 160(3):714-24. PubMed ID: 27422328
[TBL] [Abstract][Full Text] [Related]
25. Prolonged survival of a patient affected by pancreatic adenocarcinoma with massive lymphocyte and dendritic cell infiltration after interleukin-2 immunotherapy. Report of a case.
Nobili C; Degrate L; Caprotti R; Franciosi C; Leone BE; Trezzi R; Romano F; Uggeri F; Uggeri F
Tumori; 2008; 94(3):426-30. PubMed ID: 18705415
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of tislelizumab plus chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma.
Qiu HB
Thorac Cancer; 2020 Dec; 11(12):3419-3421. PubMed ID: 33043992
[No Abstract] [Full Text] [Related]
27. Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial).
Martinez Chanza N; Soukane L; Barthelemy P; Carnot A; Gil T; Casert V; Vanhaudenarde V; Sautois B; Staudacher L; Van den Brande J; Culine S; Seront E; Gizzi M; Albisinni S; Tricard T; Fantoni JC; Paesmans M; Caparica R; Roumeguere T; Awada A
BMC Cancer; 2021 Dec; 21(1):1292. PubMed ID: 34856936
[TBL] [Abstract][Full Text] [Related]
28. SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer.
Botta GP; Kato S; Patel H; Fanta P; Lee S; Okamura R; Kurzrock R
JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34375311
[TBL] [Abstract][Full Text] [Related]
29. Pancreatic intraductal papillary mucinous neoplasm in a patient with Lynch syndrome.
Flanagan MR; Jayaraj A; Xiong W; Yeh MM; Raskind WH; Pillarisetty VG
World J Gastroenterol; 2015 Mar; 21(9):2820-5. PubMed ID: 25759555
[TBL] [Abstract][Full Text] [Related]
30. Radiologic and autopsy findings in a case of fatal immune checkpoint inhibitor-associated pneumonitis.
Shea M; Rangachari D; Hallowell RW; Hollie NI; Costa DB; VanderLaan PA
Cancer Treat Res Commun; 2018; 15():17-20. PubMed ID: 30207283
[TBL] [Abstract][Full Text] [Related]
31. Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.
Joshi SS; Maron SB; Catenacci DV
Future Oncol; 2018 Feb; 14(5):417-430. PubMed ID: 29094609
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant and Neoadjuvant Therapy for Pancreatic Cancer.
Li D; O'Reilly EM
Surg Oncol Clin N Am; 2016 Apr; 25(2):311-26. PubMed ID: 27013366
[TBL] [Abstract][Full Text] [Related]
33. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer).
Hampel H; Frankel WL; Martin E; Arnold M; Khanduja K; Kuebler P; Nakagawa H; Sotamaa K; Prior TW; Westman J; Panescu J; Fix D; Lockman J; Comeras I; de la Chapelle A
N Engl J Med; 2005 May; 352(18):1851-60. PubMed ID: 15872200
[TBL] [Abstract][Full Text] [Related]
34. [Anasarca, a complication of chemotherapy with gemcitabine in two patients with pancreatic cancer].
Dahan L; Ressiot E; Cournede A; Ries P; Duluc M; Laquiere A; Laugier R; Braguer D; Seitz JF
Gastroenterol Clin Biol; 2007 Dec; 31(12):1143-5. PubMed ID: 18176375
[TBL] [Abstract][Full Text] [Related]
35. Colorectal carcinoma with double somatic mismatch repair gene inactivation: clinical and pathological characteristics and response to immune checkpoint blockade.
Wang T; Lee LH; Vyas M; Zhang L; Ganesh K; Firat C; Segal NH; Desai A; Hechtman JF; Ntiamoah P; Weiser MR; Markowitz AJ; Vakiani E; Klimstra DS; Stadler ZK; Shia J
Mod Pathol; 2019 Oct; 32(10):1551-1562. PubMed ID: 31175329
[TBL] [Abstract][Full Text] [Related]
36. Complete pathological response following down-staging chemoradiation in locally advanced pancreatic cancer: challenging the boundaries.
Khan AZ; Pitsinis V; Mudan SS
World J Gastroenterol; 2007 Dec; 13(47):6433-5. PubMed ID: 18081235
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study).
Heinrich S; Pestalozzi B; Lesurtel M; Berrevoet F; Laurent S; Delpero JR; Raoul JL; Bachellier P; Dufour P; Moehler M; Weber A; Lang H; Rogiers X; Clavien PA
BMC Cancer; 2011 Aug; 11():346. PubMed ID: 21831266
[TBL] [Abstract][Full Text] [Related]
38. [Not Available].
Salvia R; Casciani F; Sereni E; Bassi C
Presse Med; 2019 Mar; 48(3 Pt 2):e187-e197. PubMed ID: 30878338
[TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant Therapy for HER2-positive Breast Cancer.
Wuerstlein R; Harbeck N
Rev Recent Clin Trials; 2017; 12(2):81-92. PubMed ID: 28164759
[TBL] [Abstract][Full Text] [Related]
40. ASO Author Reflection: Adjuvant Chemotherapy After Neoadjuvant Chemotherapy in Pancreatic Adenocarcinoma Does Not Lead to Improved Survival in All Patients.
Olecki EJ; Gusani NJ
Ann Surg Oncol; 2021 Jun; 28(6):3123. PubMed ID: 33616769
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
